Drug launch to keep Cadila Health in focus

Zydus Cadila has launched tablet Tenglyn, the generic version of oral anti-diabetic drug Gliptins, in India. Tenglyn, priced at ₹7 a tablet, is almost a sixth of the price at which Gliptins was initially launched in India. The company had earlier launched Lipaglyn in September 2013 for treatment of diabetic dyslipidemia and hyper-triglyceridemia. Shares of Cadila Healthcare, a listed entity of the Zydus Group, will remain in focus.